Two biotechs are making their old selves walk the plank as they take on new names in the hopes of a bounteous future.
Wren Therapeutics Renamed WaveBreak, Signifying Focus on Stopping the Wave of Neurodegeneration in Parkinson's Disease,Alzheimer's Disease, and ALS at its Source
BOSTON, March 29, 2023 /PRNewswire/ -- Wren announced today the presentation of preclinical data for its first-in-class, oral inhibitors of ?-synuclein oligomer generation demonstrating potent inhibition of both oligomer production and aggregate formation in cell and mouse models used for studying Parkinson's disease progression. The data were presented in poster and oral presentations today at the International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders (AD/PD 2023) taking place from March 28–April 1 in Gothenburg, Sweden.
CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Wren Therapeutics, a biopharmaceutical company transforming drug discovery for neurodegenerative diseases, today announced the appointment of Bart Henderson as Chief Executive Officer. Wren’s unique drug discovery platform harnesses advances in the biophysics of protein assembly dynamics to target the toxic fleeting protein intermediates, the oligomers, in neurodegenerative disease pathways, and discover small molecules that can block their generation with precision.
Cambridge, UK-based biopharmaceutical company Wren Therapeutics has completed the closing of £12.4m financing, taking its total capital raised to date to around £33m.